Related Experiment Video
Updated: Jan 9, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Oncogene Mutations: The Shared Antigen Vaccines That Work?
Rodrigo Paredes1,2, S Daniel Haldar3, Shubham Pant3
1Icahn School of Medicine, Mount Sinai Morningside-West, New York, NY, USA.
Abstract:
Cancer immunotherapy has advanced through immune checkpoint inhibitors and T cell therapies, yet challenges persist in overcoming immune evasion. Neoantigen-based vaccines have shown promise, particularly in tumors with high tumor mutation burden. However, logistical barriers and tumor heterogeneity limit their scalability. Shared oncogenic driver mutations (e.g., KRAS, EGFR, IDH) offer a stable and broadly applicable alternative. Clinical trials demonstrate their immunogenicity and potential in minimal residual disease settings. Advances in vaccine delivery and immune modulation, including adjuvants and cytokine-based therapies, may further enhance efficacy. This review explores the evolution of oncogene-directed vaccines, their clinical impact, and future strategies to optimize their therapeutic potential.
Insights
Oncogene-directed cancer vaccines targeting shared mutations offer a scalable alternative to neoantigen vaccines. These vaccines show promise in clinical trials for various cancers, especially in minimal residual disease settings.
Area of Science:
- Oncology
- Immunology
- Vaccinology
Background:
- Cancer immunotherapy has progressed with immune checkpoint inhibitors and T cell therapies.
- Challenges remain in overcoming tumor immune evasion.
- Neoantigen vaccines show promise but face scalability issues due to tumor heterogeneity.
Purpose of the Study:
- To review the evolution of oncogene-directed cancer vaccines.
- To discuss their clinical impact and potential.
- To explore future strategies for optimizing vaccine efficacy.
Main Methods:
- Review of clinical trial data on oncogene-directed vaccines.
- Analysis of shared oncogenic driver mutations (e.g., KRAS, EGFR, IDH) as vaccine targets.
- Exploration of advances in vaccine delivery, adjuvants, and immune modulation.
Main Results:
- Shared oncogenic driver mutations provide a stable and broadly applicable vaccine strategy.
- Clinical trials demonstrate the immunogenicity of these vaccines.
- Potential is shown in minimal residual disease settings.
Conclusions:
- Oncogene-directed vaccines represent a promising, scalable approach to cancer immunotherapy.
- Further advances in delivery and immune modulation are expected to enhance efficacy.
- These vaccines hold significant potential for treating various cancers, particularly in overcoming immune evasion.
Related Concept Videos
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer

